Transferrin, C3 complement, haptoglobin, plasminogen and alpha 2-microglobulin in patients with urogenital tumors.
The serum levels of transferrin, haptoglobin, C3 proactivator, plasminogen and alpha 2-macroglobulin have been measured in patients suffering from urogenital cancer. In this randomized study, we found a frequent decrease of transferrin coinciding with the elevation of C3-proactivator and haptoglobin. The serum concentration of plasminogen and alpha 2-macroglobulin were rarely observed in the pathological range excluding cancer-associated changes. Tumor metabolites and/or the circulating immune complex may account for the alteration of transferrin, haptoglobin and C3-proactivator, more than primary cancer-related synthesis of these proteins.
D000230:Adenocarcinoma / Q000097:blood; D002277:Carcinoma / Q000097:blood; D003176:Complement C3 / Q000032:analysis*; D004407:Dysgerminoma / Q000097:blood; D005260:Female; D006242:Haptoglobins / Q000032:analysis; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood; D008297:Male; D010958:Plasminogen / Q000032:analysis; D011471:Prostatic Neoplasms / Q000097:blood; D013724:Teratoma / Q000097:blood; D013736:Testicular Neoplasms / Q000097:blood; D014168:Transferrin / Q000097:blood*; D001749:Urinary Bladder Neoplasms / Q000097:blood; D014565:Urogenital Neoplasms / Q000097:blood*; D000511:alpha-Macroglobulins / Q000032:analysis
D003176:Complement C3; D006242:Haptoglobins; D014168:Transferrin; D000511:alpha-Macroglobulins; D010958:Plasminogen